← Back to Clinical Trials
Recruiting NCT04212910

NCT04212910 Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04212910
Status Recruiting
Phase
Sponsor IRCCS San Raffaele
Condition Endometrium Cancer
Study Type OBSERVATIONAL
Enrollment 101 participants
Start Date 2019-07-23
Primary Completion 2025-12-31

Trial Parameters

Condition Endometrium Cancer
Sponsor IRCCS San Raffaele
Study Type OBSERVATIONAL
Phase N/A
Enrollment 101
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2019-07-23
Completion 2025-12-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Endometrial cancer (EC) is the most common gynecological malignancy in high-income countries. Prognosis and treatment are dictated by cancer histological subtype and grade coupled with surgical staging as described by Surgical International Federation of Gynecology and Obstetrics (FIGO) staging system. Surgery is the elective standard treatment and used for staging of EC. The purpose of this study is to collect images from a simultaneous PET/MRI study from which to extrapolate a preoperative, non-invasive, prognostic model.

Eligibility Criteria

Inclusion Criteria: * histopathological confirmation of a primary endometrial cancer * age \> 18 years * no contraindication to surgery (comorbidity, contraindication or lack of consent) * no contraindication to preoperative imaging * visible tumor at imaging * signed inform consent. Exclusion Criteria: * patients unsuitable for surgical intervention (comorbidity, contraindication or lack of consent, poor performance status) * age \< 18 years, c) inability to complete the needed imaging examination (ie, severe claustrophobia) * any additional medical condition that may significantly interfere with study compliance * all the contraindication for MRI (ie, pacemaker).

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology